Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it’s buying Catalent CTLT, +2.67% for $16.5 billion in cash, or$63.50 per Catalent share, a 16.5% premium to Friday’s close. The deal is a 39% premium to Catalent’s close before it announced a strategic review. Novo will sell three fill-finish sites to Novo Nordisk shortly after the deal closes. Catalent investor Elliott Investment Management said it supports the deal. ...